{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:35:06Z","timestamp":1793198106019,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Crohn\u2019s disease (CD) is an inflammatory bowel disease that requires medical treatment. The use of medications to treat CD is increasing worldwide, coinciding with the rising prevalence of the disease. However, research on the use of medications for CD has mostly focused on developed countries, and little research has been done on the status and trends in China. Thus, we conducted a nationwide study to ascertain the current status of treatment for CD patients in Chinese healthcare institutions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data on inpatient prescriptions for CD were obtained from the Hospital Prescription Analysis Cooperative Project of China. We analyzed the trends in patient numbers and prescription expenditures in seven regions of China. Subgroup analyses were performed by age, gender and drug class.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 71,654,361 patients from 70 hospitals in seven major cities of China were included in the study. From 2018 to 2022, the proportion of patients with CD increased from 0.23 per 1000 patients to 0.40 per 1000 patients. Visits by CD patients increased from 3598 to 5389, and the relevant expenditure increased from 2.83 million Chinese Yuan in to 10.61 million Chinese Yuan. The 20\u201339 age group was the most predominant age of incidence. The prevalence in males was more than twice as high as in females. 5-aminosalicylic acid, enteral\/parenteral nutrients, corticosteroids and biologicals were the main prescribed drugs. There was a clear upward trend in the use of biologicals, especially infliximab, which has become the most used prescription drug since 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This nationwide study indicates a significant increase in healthcare utilization and expenditures for CD in China from 2018 to 2022, concurrent with a paradigm shift in treatment from traditional therapies toward biologic agents, primarily infliximab. This shift, facilitated by national insurance coverage, underscores the need for pharmacoeconomic evaluations and optimized stewardship of advanced therapies. The findings establish a crucial baseline for informing future healthcare strategies for CD management in China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-026-14230-w","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T02:25:22Z","timestamp":1772072722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trends in drug use and prescription patterns for Crohn\u2019s disease patients in China, 2018\u20132022"],"prefix":"10.1186","volume":"26","author":[{"given":"Li","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linpo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"14230_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","volume":"6","author":"G Roda","year":"2020","unstructured":"Roda G, Chien NS, Kotze PG, et al. Crohn\u2019s disease. Nat Rev Dis Primers. 2020;6:22.","journal-title":"Nat Rev Dis Primers"},{"key":"14230_CR2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel JF, et al. Crohn\u2019s disease. Lancet. 2017;389:1741\u201355.","journal-title":"Lancet"},{"key":"14230_CR3","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ. Crohn\u2019s disease. Lancet. 2012;380:1590\u2013605.","journal-title":"Lancet"},{"key":"14230_CR4","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3109\/00365521.2014.962605","volume":"49","author":"R Hein","year":"2014","unstructured":"Hein R, K\u00f6ster I, Bollschweiler E, Schubert I. Prevalence of inflammatory bowel disease: estimates for 2010 and trends in Germany from a large insurance-based regional cohort. Scand. J. Gastroenterol. 2014;49:1325\u201335.","journal-title":"Scand. J. Gastroenterol"},{"key":"14230_CR5","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1097\/MIB.0000000000000103","volume":"20","author":"EI Benchimol","year":"2014","unstructured":"Benchimol EI, Manuel DG, Guttmann A, et al. Changing age demographics of inflammatory bowel disease in Ontario, Canada: a population-based cohort study of epidemiology trends. Inflamm Bowel Dis. 2014;20:1761\u201369.","journal-title":"Inflamm Bowel Dis"},{"key":"14230_CR6","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769\u201378.","journal-title":"Lancet"},{"key":"14230_CR7","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720\u201327.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"14230_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/gutjnl-2012-303661","volume":"62","author":"SC Ng","year":"2013","unstructured":"Ng SC, Bernstein CN, Vatn MH, et al. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013;62:630\u201349.","journal-title":"Gut"},{"key":"14230_CR9","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s12967-019-02164-3","volume":"17","author":"WC Lin","year":"2019","unstructured":"Lin WC, Weng MT, Tung CC, et al. Trends and risk factors of mortality analysis in patients with inflammatory bowel disease: a Taiwanese nationwide population-based study. J Transl Med. 2019;17:414.","journal-title":"J Transl Med"},{"key":"14230_CR10","unstructured":"Crohn\u2019s disease: management. London: National Institute for Health and Care Excellence (NICE); 2019 May 3."},{"key":"14230_CR11","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375:1946\u201360.","journal-title":"N Engl J Med"},{"key":"14230_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/ajg.2016.236","volume":"111","author":"PS Dulai","year":"2016","unstructured":"Dulai PS, Singh S, Jiang X, et al. The real-World effectiveness and safety of vedolizumab for Moderate-Severe Crohn\u2019s disease: results from the US VICTORY consortium. Am. J. Gastroenterol. 2016;111:1147\u201355.","journal-title":"Am. J. Gastroenterol"},{"key":"14230_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12913-020-5072-3","volume":"20","author":"Z Yu","year":"2020","unstructured":"Yu Z, Yu L, Shan C. Trends of ambulatory oral anticoagulant prescription in five major cities of China, 2012-2017. BMC Health Serv Res. 2020;20:209.","journal-title":"BMC Health Serv Res"},{"key":"14230_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s10194-024-01775-6","volume":"25","author":"J Huang","year":"2024","unstructured":"Huang J, Wang X, Jin Y, et al. Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis. J Headache Pain. 2024;25:62.","journal-title":"J Headache Pain"},{"key":"14230_CR15","first-page":"201","volume":"11","author":"G Han","year":"2015","unstructured":"Han G, Yu Z, Ma K. Current status of parenteral nutrition and enteral nutrition application: an assessment of nutritional prescriptions from 59 hospitals in the People\u2019s Republic of China. Ther Clin Risk Manag. 2015;11:201\u201307.","journal-title":"Ther Clin Risk Manag"},{"key":"14230_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.glt.2023.03.002","volume":"5","author":"J Liu","year":"2023","unstructured":"Liu J, Zhai X, Yan W, et al. Long-term impact of the COVID-19 pandemic on health services utilization in China: a nationwide longitudinal study. Glob Transit. 2023;5:21\u201328.","journal-title":"Glob Transit"},{"key":"14230_CR17","first-page":"100122","volume":"9","author":"H Xiao","year":"2021","unstructured":"Xiao H, Dai X, Wagenaar BH, et al. The impact of the COVID-19 pandemic on health services utilization in China: time-series analyses for 2016-2020. Lancet Reg Health West Pac. 2021;9:100122.","journal-title":"Lancet Reg Health West Pac"},{"key":"14230_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","volume":"12","author":"AN Ananthakrishnan","year":"2015","unstructured":"Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205\u201317.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"14230_CR19","first-page":"277","volume":"91","author":"L de la Cal Ja","year":"1999","unstructured":"de la Cal Ja L, Cant\u00f3n, Hermida C, et al. Estimated incidence of inflammatory bowel disease in Argentina and Panama (1987-1993). Rev Esp Enferm Dig. 1999;91:277\u201386.","journal-title":"Rev Esp Enferm Dig"},{"key":"14230_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46\u2013e30.","journal-title":"Gastroenterology"},{"key":"14230_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ibd.20756","volume":"15","author":"AM Lowe","year":"2009","unstructured":"Lowe AM, Roy PO, B-Poulin M, et al. Epidemiology of Crohn\u2019s disease in Qu\u00e9bec, Canada. Inflamm Bowel Dis. 2009;15:429\u201335.","journal-title":"Inflamm Bowel Dis"},{"key":"14230_CR22","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ibd.20310","volume":"14","author":"SK Yang","year":"2008","unstructured":"Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005. A KASID study. Inflamm Bowel Dis. 2008;14:542\u201349.","journal-title":"Inflamm Bowel Dis"},{"key":"14230_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/ibd.20321","volume":"14","author":"E Cachia","year":"2008","unstructured":"Cachia E, Calleja N, Aakeroy R, et al. Incidence of inflammatory bowel disease in Malta between 1993 and 2005: a retrospective study. Inflamm Bowel Dis. 2008;14:550\u201353.","journal-title":"Inflamm Bowel Dis"},{"key":"14230_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.crohns.2008.12.002","volume":"3","author":"MJ Romberg-Camps","year":"2009","unstructured":"Romberg-Camps MJ, Hesselink-van de Kruijs MA, Schouten LJ, et al. Inflammatory bowel disease in South Limburg (the Netherlands) 1991-2002. Incidence, diagnostic delay, and seasonal variations in onset of symptoms. J Crohns Colitis. 2009;3:115\u201324.","journal-title":"J Crohns Colitis"},{"key":"14230_CR25","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/ecco-jcc\/jjz081","volume":"13","author":"SH Park","year":"2019","unstructured":"Park SH, Kim YJ, Rhee KH, et al. A 30-year trend analysis in the Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015. J Crohns Colitis. 2019;13:1410\u201317.","journal-title":"J Crohns Colitis"},{"key":"14230_CR26","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1097\/MIB.0000000000000846","volume":"22","author":"SC Ng","year":"2016","unstructured":"Ng SC, Leung WK, Shi HY, et al. Epidemiology of inflammatory bowel disease from 1981 to 2014: results from a Territory-wide population-based registry in Hong Kong. Inflamm Bowel Dis. 2016;22:1954\u201360.","journal-title":"Inflamm Bowel Dis"},{"key":"14230_CR27","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1007\/s10620-015-3630-z","volume":"60","author":"CJ Kuo","year":"2015","unstructured":"Kuo CJ, Yu KH, See LC, et al. The trend of inflammatory bowel diseases in Taiwan: a population-based study. Dig Dis Sci. 2015;60:2454\u201362.","journal-title":"Dig Dis Sci"},{"key":"14230_CR28","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00535-019-01603-8","volume":"54","author":"Y Murakami","year":"2019","unstructured":"Murakami Y, Nishiwaki Y, Oba MS, et al. Estimated prevalence of ulcerative colitis and Crohn\u2019s disease in Japan in 2014: an analysis of a nationwide survey. J Gastroenterol. 2019;54:1070\u201377.","journal-title":"J Gastroenterol"},{"key":"14230_CR29","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/ibd\/izaa127","volume":"27","author":"M Noureldin","year":"2021","unstructured":"Noureldin M, Cohen-Mekelburg S, Mahmood A, et al. Trends of 5-aminosalicylate medication use in patients with Crohn disease. Inflamm Bowel Dis. 2021;27:516\u201321.","journal-title":"Inflamm Bowel Dis"},{"key":"14230_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/ajg.2010.317","volume":"106","author":"AC Ford","year":"2011","unstructured":"Ford AC, Khan KJ, Talley NJ, et al. 5-aminosalicylates prevent relapse of Crohn\u2019s disease after surgically induced remission: systematic review and meta-analysis. Am. J. Gastroenterol. 2011;106:413\u201320.","journal-title":"Am. J. Gastroenterol"},{"key":"14230_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020;14:4\u201322.","journal-title":"J Crohns Colitis"},{"key":"14230_CR32","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","volume":"160","author":"JD Feuerstein","year":"2021","unstructured":"Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical Practice guidelines on the medical management of moderate to severe luminal and Perianal Fistulizing Crohn\u2019s disease. Gastroenterology. 2021;160:2496\u2013508.","journal-title":"Gastroenterology"},{"key":"14230_CR33","doi-asserted-by":"crossref","unstructured":"Benchimol EI, Seow CH, Steinhart AH, et al. Traditional corticosteroids for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2008: CD006792.","DOI":"10.1002\/14651858.CD006792.pub2"},{"key":"14230_CR34","doi-asserted-by":"crossref","unstructured":"Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2003: CD000301.","DOI":"10.1002\/14651858.CD000301"},{"key":"14230_CR35","doi-asserted-by":"crossref","unstructured":"Chande N, Patton PH, Tsoulis DJ, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2015: CD000067.","DOI":"10.1002\/14651858.CD000067.pub3"},{"key":"14230_CR36","doi-asserted-by":"crossref","unstructured":"McDonald JW, Wang Y, Tsoulis DJ, et al. Methotrexate for induction of remission in refractory Crohn\u2019s disease. Cochrane Database Syst Rev. 2014: CD003459.","DOI":"10.1002\/14651858.CD003459.pub4"},{"key":"14230_CR37","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/gut.2010.227884","volume":"60","author":"L Peyrin-Biroulet","year":"2011","unstructured":"Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn\u2019s disease. Gut. 2011;60:930\u201336.","journal-title":"Gut"},{"key":"14230_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/ajg.2013.402","volume":"109","author":"S Chatu","year":"2014","unstructured":"Chatu S, Subramanian V, Saxena S, et al. The role of thiopurines in reducing the need for surgical resection in Crohn\u2019s disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 2014;109:23\u201335.","journal-title":"Am. J. Gastroenterol"},{"key":"14230_CR39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/1751-2980.12414","volume":"17","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Xia JJ, Xiao P, et al. Standard-dose versus low-dose azathioprine in the treatment of Crohn\u2019s disease: a prospective randomized study. J Dig Dis. 2016;17:747\u201355.","journal-title":"J Dig Dis"},{"key":"14230_CR40","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","volume":"141","author":"L Peyrin-Biroulet","year":"2011","unstructured":"Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621\u201328.e285.","journal-title":"Gastroenterology"},{"key":"14230_CR41","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","volume":"374","author":"L Beaugerie","year":"2009","unstructured":"Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617\u201325.","journal-title":"Lancet"},{"key":"14230_CR42","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","volume":"8","author":"JF Rahier","year":"2014","unstructured":"Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443\u201368.","journal-title":"J Crohns Colitis"},{"key":"14230_CR43","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/gutjnl-2017-315568","volume":"68","author":"J Burisch","year":"2019","unstructured":"Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn\u2019s disease during the first 5 years after diagnosis in a European population-based inception cohort: an epi-IBD study. Gut. 2019;68:423\u201333.","journal-title":"Gut"},{"key":"14230_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12876-018-0746-6","volume":"18","author":"Z Kurti","year":"2018","unstructured":"Kurti Z, Ilias A, Gonczi L, et al. Therapeutic preferences and outcomes in newly diagnosed patients with Crohn\u2019s diseases in the biological era in Hungary: a nationwide study based on the national health insurance fund database. BMC Gastroenterol. 2018;18:23.","journal-title":"BMC Gastroenterol"},{"key":"14230_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12664-020-01031-0","volume":"39","author":"BS Dhindsa","year":"2020","unstructured":"Dhindsa BS, Dhaliwal A, Mashiana HS, et al. Reversal of anti-drug antibodies against tumor necrosis factor inhibitors with addition of immunomodulators: a systematic review and meta-analysis. Indian J Gastroenterol. 2020;39:153\u201360.","journal-title":"Indian J Gastroenterol"},{"key":"14230_CR46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00384-023-04349-1","volume":"38","author":"J Stallhofer","year":"2023","unstructured":"Stallhofer J, Guse J, Kesselmeier M, et al. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease. Int J Colorectal Dis. 2023;38:54.","journal-title":"Int J Colorectal Dis"},{"key":"14230_CR47","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710.","journal-title":"N Engl J Med"},{"key":"14230_CR48","doi-asserted-by":"crossref","unstructured":"D\u2019Amico F, Peyrin-Biroulet L, Danese S. Ustekinumab in Crohn\u2019s disease: new data for positioning in treatment algorithm. J Crohns Colitis. 2022;16:ii30\u201341.","DOI":"10.1093\/ecco-jcc\/jjac011"},{"key":"14230_CR49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/ibd\/izac065","volume":"29","author":"A Buisson","year":"2023","unstructured":"Buisson A, Blanco L, Manlay L, et al. Top-down versus Step-up strategies to prevent postoperative recurrence in Crohn\u2019s disease. Inflamm Bowel Dis. 2023;29:185\u201394.","journal-title":"Inflamm Bowel Dis"},{"key":"14230_CR50","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/MPG.0000000000003643","volume":"76","author":"E Payen","year":"2023","unstructured":"Payen E, Neuraz A, Zenzeri L, et al. Adalimumab therapy in pediatric Crohn disease: a 2-year follow-up comparing \u201ctop-down\u201d and \u201cStep-up\u201d strategies. J Pediatr Gastroenterol Nutr. 2023;76:166\u201373.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"14230_CR51","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/j.1440-1746.2011.06984.x","volume":"27","author":"L Prideaux","year":"2012","unstructured":"Prideaux L, Kamm MA, De Cruz P, et al. Comparison of clinical characteristics and management of inflammatory bowel disease in Hong Kong versus Melbourne. J. Gastroenterol. Hepatol. 2012;27:919\u201327.","journal-title":"J. Gastroenterol. Hepatol"},{"key":"14230_CR52","doi-asserted-by":"crossref","unstructured":"Church PC, Hyams J, Ruemmele F, et al. The continental divide: anti-TNF use in pediatric IBD is different in North America compared to other parts of the World. Can J Gastroenterol Hepatol. 2018;3190548.","DOI":"10.1155\/2018\/3190548"},{"key":"14230_CR53","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.clnu.2022.12.004","volume":"42","author":"SC Bischoff","year":"2023","unstructured":"Bischoff SC, Bager P, Escher J, et al. ESPEN guideline on clinical nutrition in inflammatory bowel disease. Clin Nutr. 2023;42:352\u201379.","journal-title":"Clin Nutr"},{"key":"14230_CR54","unstructured":"Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1\u2013106."},{"key":"14230_CR55","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","volume":"8","author":"FM Ruemmele","year":"2014","unstructured":"Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn\u2019s disease. J Crohns Colitis. 2014;8:1179\u2013207.","journal-title":"J Crohns Colitis"},{"key":"14230_CR56","doi-asserted-by":"crossref","unstructured":"Narula N, Dhillon A, Zhang D, et al. Enteral nutritional therapy for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2018;4:CD000542.","DOI":"10.1002\/14651858.CD000542.pub3"},{"key":"14230_CR57","doi-asserted-by":"publisher","first-page":"1949096","DOI":"10.1080\/19490976.2021.1949096","volume":"13","author":"E Caparr\u00f3s","year":"2021","unstructured":"Caparr\u00f3s E, Wiest R, Scharl M, et al. Dysbiotic microbiota interactions in Crohn\u2019s disease. Gut Microbes. 2021;13:1949096.","journal-title":"Gut Microbes"},{"key":"14230_CR58","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1053\/j.gastro.2023.01.017","volume":"164","author":"R Gowen","year":"2023","unstructured":"Gowen R, Gamal A, Di Martino L, et al. Modulating the microbiome for Crohn\u2019s disease treatment. Gastroenterology. 2023;164:828\u201340.","journal-title":"Gastroenterology"},{"key":"14230_CR59","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1039\/D0FO02786C","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, Yin F, Huang L, et al. Long-term and continuous administration of Bacillus subtilis during remission effectively maintains the remission of inflammatory bowel disease by protecting intestinal integrity, regulating epithelial proliferation, and reshaping microbial structure and function. Food Funct. 2021;12:2201\u201310.","journal-title":"Food Funct"},{"key":"14230_CR60","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.gastro.2003.08.025","volume":"125","author":"WJ Sandborn","year":"2003","unstructured":"Sandborn WJ, Fazio VW, Feagan BG, et al. American Gastroenterological Association clinical Practice committee. AGA technical review on perianal Crohn\u2019s disease. Gastroenterology. 2003;125:1508\u201330.","journal-title":"Gastroenterology"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14230-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14230-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14230-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:53:42Z","timestamp":1781636022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14230-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14230"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14230-w","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"1 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from the First Affiliated Hospital of the Zhejiang Chinese Medical University. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board, the national regulations of China, and the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"454"}}